La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Immutep a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Immutep..

Immutep (NASDAQ:IMMP) Azioni, Catena delle Opzioni

Immutep

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

Press Releases

Patient Enrolment Completed for EFTISARC-NEO Phase II Trial

Immutep Quarterly Activities Report Q2 FY25

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025

First Patient Dosed in Immutep's TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Immutep to Participate in Upcoming Investor Conferences

Immutep Quarterly Activities Report Q3 FY25

Immutep's Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1

Immutep's Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases

Comments

Immutep

Immutep (IMMP) Opzioni

Immutep (NASDAQ:IMMP) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO